Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team.

Lancet. 2009 Mar 28;373(9669):1097-104. doi: 10.1016/S0140-6736(09)60500-6. Epub 2009 Mar 18. Erratum in: Lancet. 2009 Aug 8;374(9688):450.

2.

Imatinib: as adjuvant therapy for gastrointestinal stromal tumour.

Sanford M, Scott LJ.

Drugs. 2010 Oct 22;70(15):1963-72. doi: 10.2165/11205000-000000000-00000. Review.

PMID:
20883053
3.

Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.

Dretzke J, Round J, Connock M, Tubeuf S, Pennant M, Fry-Smith A, Hulme C, McCabe C, Meads C.

Health Technol Assess. 2010 Oct;14(Suppl. 2):63-70. doi: 10.3310/hta14suppl2/09. Review.

4.

[Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors].

Heger U, Weitz J, Lordick F.

Chirurg. 2008 Jul;79(7):630-7. doi: 10.1007/s00104-008-1526-6. Review. German.

PMID:
18548219
5.

[Gastrointestinal stromal tumour (GIST): current standards in multimodal management].

Reichardt P, Reichardt A.

Zentralbl Chir. 2011 Aug;136(4):359-63. doi: 10.1055/s-0031-1271596. Epub 2011 Aug 23. Review. German.

PMID:
21863513
6.

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.

Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D.

Health Technol Assess. 2005 Jul;9(25):1-142. Review.

7.

Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review.

Cirocchi R, Farinella E, La Mura F, Cavaliere D, Avenia N, Verdecchia GM, Giustozzi G, Noya G, Sciannameo F.

Tumori. 2010 May-Jun;96(3):392-9. Review.

PMID:
20845798
8.

New fronts in the adjuvant treatment of GIST.

Reichardt P, Joensuu H, Blay JY.

Cancer Chemother Pharmacol. 2013 Oct;72(4):715-23. doi: 10.1007/s00280-013-2248-0. Epub 2013 Aug 11. Review.

PMID:
23934322
9.

Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review.

Essat M, Cooper K.

Int J Cancer. 2011 May 1;128(9):2202-14. doi: 10.1002/ijc.25827. Review.

10.
11.

Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?

Blay JY, Adenis A, Ray-Coquard I, Cassier PA, Le Cesne A.

Curr Opin Oncol. 2009 Jul;21(4):360-6. doi: 10.1097/CCO.0b013e32832c95f8. Review.

PMID:
19509502
12.

Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.

Le Cesne A, Blay JY, Reichardt P, Joensuu H.

Oncologist. 2013;18(11):1192-9. doi: 10.1634/theoncologist.2012-0361. Epub 2013 Oct 17. Review.

13.

Intolerance to imatinib in gastrointestinal stromal tumors: a case report and a review of literature.

Akasbi Y, Arifi S, Brahmi SA, El Mrabet FZ, Mellas N, Mernisi FZ, El Mesbahi O.

J Gastrointest Cancer. 2014 Dec;45 Suppl 1:71-3. doi: 10.1007/s12029-013-9531-5. Review. No abstract available.

PMID:
24006243
14.
15.

[Surgical treatment of gastrointestinal stromal tumors].

Bareck E, Längle F, Zacherl J.

Wien Med Wochenschr. 2009;159(15-16):393-8. doi: 10.1007/s10354-009-0691-7. Review. German.

PMID:
19696983
16.

[Treatment of extensive disease].

Ploner F, Eisterer W.

Wien Med Wochenschr. 2009;159(15-16):403-7. doi: 10.1007/s10354-009-0690-8. Review. German.

PMID:
19696985
17.

Gastrointestinal stromal tumor in a child and review of the literature.

Hayashi Y, Okazaki T, Yamataka A, Yanai T, Yamashiro Y, Tsurumaru M, Kajiyama Y, Miyano T.

Pediatr Surg Int. 2005 Nov;21(11):914-7. Review.

PMID:
16240136
18.

[Multimodality therapy concepts for soft tissue sarcomas].

Wendtner CM, Delank S, Eich H.

Internist (Berl). 2010 Nov;51(11):1388-96. doi: 10.1007/s00108-010-2672-8. Review. German.

PMID:
20938627
19.

Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis.

Zhi X, Jiang B, Yu J, Røe OD, Qin J, Ni Q, Sun L, Xu M, Zhu J, Ma L.

Sci Rep. 2016 Feb 19;6:21541. doi: 10.1038/srep21541. Review.

20.

[Mesenteric stromal tumor: report of a rare case and review of literature].

Seck M, Ka I, Cissé M, Touré AO, Thiam O, Gueye ML, Dieng M, Touré CT.

Pan Afr Med J. 2015 Aug 27;21:306. doi: 10.11604/pamj.2015.21.306.6754. eCollection 2015. Review. French. No abstract available.

Supplemental Content

Support Center